Abstract:Yue Song, 1, &ast Qing-Qing Dong, 2, &ast Yi-Ke Ni, 3 Xiao-Ling Xu, 3 Chao-Xiang Chen, 3 Wei Chen 2 1 Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People's Republic of China; 2 ICU, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China; 3 Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang Province, 310015, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao-Ling Xu; Chao-Xiang Chen, Shulan International Medical College, Zhejiang Shuren University, 8 Shuren Street, Hangzhou, 310015, People's Republic of China, Email ; Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that have the capability to induce specific protein degradation. While playing a revolutionary role in effectively degrading the protein of interest (POI), PROTACs encounter certain limitations that impede their clinical translation. These limitations encompass off-target effects, inadequate cell membrane permeability, and the hook effect. The advent of nanotechnology presents a promising avenue to surmount the challenges associated with conventional PROTACs. The utilization of nano-proteolysis targeting chimeras (nano-PROTACs) holds the potential to enhance specific tissue accumulation, augment membrane permeability, and enable controlled release. Consequently, this approach has the capacity to significantly enhance the controllable degradation of target proteins. Additionally, they enable a synergistic effect by combining with other therapeutic strategies. This review comprehensively summarizes the structural basis, advantages, and limitations of PROTACs. Furthermore, it highlights the latest advancements in nanosystems engineered for delivering PROTACs, as well as the development of nano-sized PROTACs employing nanocarriers as linkers. Moreover, it delves into the underlying principles of nanotechnology tailored specifically for PROTACs, alongside the current prospects of clinical research. In conclusion, the integration of nanotechnology into PROTACs harbors vast potential in enhancing the anti-tumor treatment response and expediting clinical translation. Keywords: Proteolysis-targeting chimeras, nanotechnology, delivery, linker, designing principles Graphical Proteolysis-targeting chimeras (PROTAC) are a class of small molecule drugs designed to target and degrade intracellular proteins. 1 PROTAC consists of three parts; E3 ubiquitin ligase ligand, target protein ligand, and linker for conjugation. Due to the proper hydrophile-lipophile balance, PROTAC may be rapidly internalized into the cytoplasm, facilitating effective degradation of the protein of interest (POI). The target protein ligand and E3 ubiquitin ligase ligand guide PROTAC to recognize the target protein and E3 ubiquitin ligase, respectively, resulting in the formation of a ternary complex. As E3 ubiquitin ligase is an enzyme that can transfer ubiquitin molecules to a lysine of the target protein, the target protein turns to proteins marked with ubiquitin. The ubiquitin-proteasome systems rapidly and irreversibly initiate the degradation process, contributing to reduced levels of target proteins. 2–5 The schematic route of PROTAC is illustrated in Figure 1. Figure 1 The mechanism of PROTACs. Figure generated using BioRender, Agreement number: KE26PEXHAO. PROTAC offers several advantages over traditional small molecule inhibitors (SMIs), as described below, and puts it ahead of alternative drugs: 1) Changing the target from "undruggable" to "druggable". 6–10 "Undruggable" proteins refer to therapeutic targets with clinical significance that are characterized by the lack of definite ligand binding pockets, non-catalytic interaction regions, and unresolved crystal structures, accounting for 80% of proteins in human cells. Antibodies with high molecular weights cannot enter because the majority are located in cells or nuclei. Moreover, the protein surface is relatively smooth without evident "pockets", thus, SMIs cannot be firmly grasped. Hence, these target proteins (including C-Myc, NF-κB, and brachyury (TBXTA)) are difficult or impossible to make into drugs via traditional methods. Conversely, PROTACs only require weak binding with the target protein to specifically "label" it regardless of catalytic ability or binding pockets of an enzyme. Currently, approximately 80% of the "undruggable" proteins may be solved by PROTAC technology. 11,12 2) Overcoming drug resistance caused by mutation/overexpression of target p -Abstract Truncated-

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Precise Modulation of Protein Degradation by Smart PROTACs

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

The Present and Future of Novel Protein Degradation Technology

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Degradation of intrinsically disordered proteins using proteolysis targeting nanobody conjugate

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development